Glenmark Generics Inc., USA, the United States subsidiary of Glenmark Generics has been granted final approval from the United States Food and Drug Administration (USFDA) for Rizatriptan Benzoate Tablets, its generic version of Merck’s Maxalt Tablets. The company has commenced shipping immediately upon approval.
The approval is for the 5 mg and 10 mg of Rizatriptan. According to IMS Health for the 12 month period ending Sept 2012, Rizatriptan Benzoate Tablets achieved sales of $333 million.
Glenmark’s current portfolio consists of 82 products authorized for distribution in the US, marketplace and 46 ANDA’s pending approval with the USFDA. Besides, the company remains focused on strategic planning and development and continues its aggressive filing schedule for new ANDA submissions.
Glenmark Generics is a subsidiary of Glenmark Pharmaceuticals (Glenmark) and aims to be a global integrated Generic and API leader. GGL has an established presence in North America, a developing EU presence and Argentina and maintains marketing front-ends in these countries.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1847.30 |
| Dr. Reddys Lab | 1293.25 |
| Cipla | 1347.70 |
| Zydus Lifesciences | 938.90 |
| Lupin | 2377.90 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: